Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABVX ABIVAX Société Anonyme	$6.84 -1.3%	$6.65	$4.77 ▼ $16.63	$433.79M	0.45	131,861 shs	26,965 shs
AGIO Agios Pharmaceuticals	$29.45 +0.6%	$30.30	$23.42 ▼ $62.58	$1.69B	0.83	705,097 shs	358,865 shs
ANIP ANI Pharmaceuticals	$69.82 +0.3%	$64.24	$52.50 ▼ $70.55	$1.52B	0.49	273,758 shs	205,402 shs
CGON CG Oncology	$22.37 +3.9%	$23.61	$14.80 ▼ $46.99	$1.70B	1.24	740,605 shs	1.64 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABVX ABIVAX Société Anonyme	0.00%	+6.87%	+0.29%	+12.32%	-56.95%
AGIO Agios Pharmaceuticals	0.00%	+6.47%	-4.51%	-14.54%	-7.01%
ANIP ANI Pharmaceuticals	0.00%	+0.88%	+2.14%	+19.07%	+6.71%
CGON CG Oncology	0.00%	+8.38%	-16.96%	-27.35%	-37.95%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABVX ABIVAX Société Anonyme	2.1756 of 5 stars	3.5	3.0	0.0	2.1	0.8	0.6
AGIO Agios Pharmaceuticals	4.0931 of 5 stars	3.3	2.0	4.2	2.6	0.8	1.9
ANIP ANI Pharmaceuticals	4.4249 of 5 stars	3.5	3.0	3.3	2.8	3.3	1.3
CGON CG Oncology	1.3225 of 5 stars	3.5	0.0	0.0	3.7	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABVX ABIVAX Société Anonyme	3.00	Buy	$38.00	455.56% Upside
AGIO Agios Pharmaceuticals	2.56	Moderate Buy	$56.57	92.09% Upside
ANIP ANI Pharmaceuticals	3.00	Buy	$80.13	14.76% Upside
CGON CG Oncology	3.00	Buy	$59.33	165.24% Upside

Current Analyst Ratings Breakdown

Latest ABVX, AGIO, CGON, and ANIP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/21/2025	ANIP ANI Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$62.00 ➝ $65.00
4/16/2025	CGON CG Oncology	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Perform	$23.00
4/11/2025	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$86.00 ➝ $86.00
3/31/2025	CGON CG Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
3/25/2025	CGON CG Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
3/20/2025	ABVX ABIVAX Société Anonyme	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight	$12.00
3/17/2025	ANIP ANI Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$94.00 ➝ $94.00
3/14/2025	ANIP ANI Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$80.00
3/12/2025	ANIP ANI Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$85.00
3/7/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$55.00 ➝ $55.00
3/5/2025	ANIP ANI Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$84.00 ➝ $86.00

(Data available from 4/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABVX ABIVAX Société Anonyme	N/A	N/A	N/A	N/A	$3.37 per share	N/A
AGIO Agios Pharmaceuticals	$36.50M	46.23	N/A	N/A	$27.02 per share	1.09
ANIP ANI Pharmaceuticals	$614.38M	2.47	$7.73 per share	9.03	$21.13 per share	3.30
CGON CG Oncology	$1.14M	1,496.90	N/A	N/A	($1.94) per share	-11.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABVX ABIVAX Société Anonyme	-$159.90M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
AGIO Agios Pharmaceuticals	$673.72M	$11.34	2.60	N/A	N/A	1,845.92%	-2.51%	-2.26%	5/1/2025 (Estimated)
ANIP ANI Pharmaceuticals	$18.78M	-$1.14	N/A	16.58	N/A	-1.28%	15.87%	6.88%	5/9/2025 (Estimated)
CGON CG Oncology	-$48.61M	-$1.42	N/A	N/A	N/A	-10,642.98%	-18.97%	-15.36%	5/8/2025 (Estimated)

Latest ABVX, AGIO, CGON, and ANIP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/9/2025	Q1 2025	ANIP ANI Pharmaceuticals	$1.37	N/A	N/A	N/A	$179.75 million	N/A
5/8/2025	Q1 2025	CGON CG Oncology	-$0.36	N/A	N/A	N/A	N/A	N/A
5/1/2025	Q1 2025	AGIO Agios Pharmaceuticals	-$1.80	N/A	N/A	N/A	$9.86 million	N/A
3/25/2025	Q4 2024	CGON CG Oncology	-$0.37	-$0.48	-$0.11	-$0.48	$0.11 million	$0.46 million
2/20/2025	Q4 2024	AGIO Agios Pharmaceuticals	-$1.69	-$1.74	-$0.05	-$1.74	$9.35 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABVX ABIVAX Société Anonyme	N/A	N/A	N/A	N/A	N/A
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ANIP ANI Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABVX ABIVAX Société Anonyme	0.48	3.04	N/A
AGIO Agios Pharmaceuticals	N/A	11.90	11.56
ANIP ANI Pharmaceuticals	1.52	2.74	1.97
CGON CG Oncology	N/A	35.32	35.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABVX ABIVAX Société Anonyme	47.91%
AGIO Agios Pharmaceuticals	N/A
ANIP ANI Pharmaceuticals	76.05%
CGON CG Oncology	26.56%

Insider Ownership

Company	Insider Ownership
ABVX ABIVAX Société Anonyme	N/A
AGIO Agios Pharmaceuticals	4.93%
ANIP ANI Pharmaceuticals	12.70%
CGON CG Oncology	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABVX ABIVAX Société Anonyme	61	63.42 million	N/A	Not Optionable
AGIO Agios Pharmaceuticals	390	57.30 million	54.47 million	Optionable
ANIP ANI Pharmaceuticals	600	21.77 million	18.36 million	Optionable
CGON CG Oncology	61	76.22 million	N/A	Optionable

ABVX, AGIO, CGON, and ANIP Headlines

Recent News About These Companies

CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025

April 26 at 4:11 PM | seekingalpha.com

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting

April 26 at 4:10 PM | globenewswire.com

XTX Topco Ltd Takes $573,000 Position in CG Oncology, Inc. (NASDAQ:CGON)

April 22, 2025 | marketbeat.com

CG Oncology, Inc. (NASDAQ:CGON) Shares Acquired by JPMorgan Chase & Co.

April 21, 2025 | marketbeat.com

Marshall Wace LLP Has $41.82 Million Holdings in CG Oncology, Inc. (NASDAQ:CGON)

April 20, 2025 | marketbeat.com

Geode Capital Management LLC Has $33.18 Million Stock Position in CG Oncology, Inc. (NASDAQ:CGON)

April 19, 2025 | marketbeat.com

CG Oncology (NASDAQ:CGON) Now Covered by Scotiabank

April 18, 2025 | marketbeat.com

224,580 Shares in CG Oncology, Inc. (NASDAQ:CGON) Acquired by Walleye Capital LLC

April 18, 2025 | marketbeat.com

Scotiabank Begins Coverage on CG Oncology (NASDAQ:CGON)

April 18, 2025 | americanbankingnews.com

CG Oncology initiated with a Sector Perform at Scotiabank

April 18, 2025 | markets.businessinsider.com

Scotiabank Initiates Coverage of CG Oncology (CGON) with Sector Perform Recommendation

April 18, 2025 | msn.com

Affinity Asset Advisors LLC Invests $2.87 Million in CG Oncology, Inc. (NASDAQ:CGON)

April 17, 2025 | marketbeat.com

CenterBook Partners LP Sells 73,188 Shares of CG Oncology, Inc. (NASDAQ:CGON)

April 11, 2025 | marketbeat.com

CG Oncology, Inc. (NASDAQ:CGON) Receives Average Rating of "Buy" from Analysts

April 10, 2025 | marketbeat.com

CG Oncology (NASDAQ:CGON) Sets New 52-Week Low - What's Next?

April 9, 2025 | marketbeat.com

ADAR1 Capital Management LLC Buys 72,646 Shares of CG Oncology, Inc. (NASDAQ:CGON)

April 9, 2025 | marketbeat.com

Massachusetts Financial Services Co. MA Sells 22,788 Shares of CG Oncology, Inc. (NASDAQ:CGON)

April 9, 2025 | marketbeat.com

Buy Rating Affirmed for CG Oncology Amid Promising Trial Data and Market Opportunities

April 8, 2025 | tipranks.com

Vanguard Group Inc. Has $168.10 Million Stock Position in CG Oncology, Inc. (NASDAQ:CGON)

April 8, 2025 | marketbeat.com

Alliancebernstein L.P. Purchases 692,982 Shares of CG Oncology, Inc. (NASDAQ:CGON)

April 7, 2025 | marketbeat.com

Franklin Resources Inc. Buys 45,698 Shares of CG Oncology, Inc. (NASDAQ:CGON)

April 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABVX, AGIO, CGON, and ANIP Company Descriptions

ABIVAX Société Anonyme NASDAQ:ABVX

$6.84 -0.09 (-1.30%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$6.88 +0.04 (+0.58%)

As of 04/25/2025 05:37 PM Eastern

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults. ABIVAX Société Anonyme was incorporated in 2013 and is headquartered in Paris, France.

Agios Pharmaceuticals NASDAQ:AGIO

$29.45 +0.19 (+0.65%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$28.82 -0.63 (-2.12%)

As of 04/25/2025 04:20 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

ANI Pharmaceuticals NASDAQ:ANIP

$69.82 +0.18 (+0.26%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$69.82 +0.01 (+0.01%)

As of 04/25/2025 04:41 PM Eastern

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

CG Oncology NASDAQ:CGON

$22.37 +0.85 (+3.95%)

Closing price 04/25/2025 04:00 PM Eastern

Extended Trading

$27.61 +5.24 (+23.41%)

As of 04/25/2025 07:59 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time